CA2030237A1 - Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist - Google Patents

Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Info

Publication number
CA2030237A1
CA2030237A1 CA2030237A CA2030237A CA2030237A1 CA 2030237 A1 CA2030237 A1 CA 2030237A1 CA 2030237 A CA2030237 A CA 2030237A CA 2030237 A CA2030237 A CA 2030237A CA 2030237 A1 CA2030237 A1 CA 2030237A1
Authority
CA
Canada
Prior art keywords
alcohol
extinguishing
opiate antagonist
transdermally administered
treating alcoholism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2030237A
Other languages
French (fr)
Other versions
CA2030237C (en
Inventor
John David Sinclair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Contral Clinics Oy
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2030237A1 publication Critical patent/CA2030237A1/en
Application granted granted Critical
Publication of CA2030237C publication Critical patent/CA2030237C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Abstract

The use of an opiate antagonist for the preparation of a pharmaceutical composition to be transdermally administered simultaneously or separately sequentially with alcohol and a device for transdermally administering the antagonist. The device is a package containing a fixed dose of opiate antagonist, a vehicle and a permeation enhancer.
CA002030237A 1989-11-20 1990-11-19 Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist Expired - Lifetime CA2030237C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US439,050 1989-11-20
US07/439,050 US5096715A (en) 1989-11-20 1989-11-20 Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Publications (2)

Publication Number Publication Date
CA2030237A1 true CA2030237A1 (en) 1991-05-21
CA2030237C CA2030237C (en) 1997-12-30

Family

ID=23743078

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002030237A Expired - Lifetime CA2030237C (en) 1989-11-20 1990-11-19 Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Country Status (10)

Country Link
US (1) US5096715A (en)
EP (1) EP0429039B1 (en)
AT (1) ATE119393T1 (en)
AU (1) AU639042B2 (en)
CA (1) CA2030237C (en)
DE (1) DE69017596T2 (en)
DK (1) DK0429039T3 (en)
ES (1) ES2074513T3 (en)
FI (1) FI905718A (en)
NZ (2) NZ247173A (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
DE4223004A1 (en) * 1992-07-13 1994-01-20 Liedtke Pharmed Gmbh Single-dose semi-solid topical dosage form for transdermal therapy
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5552153A (en) * 1994-04-28 1996-09-03 Hoffman-La Roche Inc. Pharmaceutical composition for transdermal delivery
US5580574A (en) * 1994-04-28 1996-12-03 Hoffmann-La Roche Inc. Pharmaceutical composition for transdermal delivery
DE4423850A1 (en) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermal delivery device for naloxone hydrochloride
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
RU2241458C2 (en) 1997-12-22 2004-12-10 Эро-Селтик, С.А. Combinations of agonist/antagonist for opioid
CN1204890C (en) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 Method for preventing abuse of opioid dosage forms
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
DE69939019D1 (en) * 1998-07-07 2008-08-14 Transdermal Technologies Inc COMPOSITIONS FOR THE RAPID AND NON-IRRITANT TRANSDERMAL ADMINISTRATION OF PHARMACEUTICALS AND METHOD FOR FORMULING THEREOF AND THEIR ADMINISTRATION
WO2001040269A2 (en) * 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
JP2003522144A (en) 2000-02-08 2003-07-22 ユーロ−セルティーク，エス．エイ． Controlled release compositions comprising opioid agonists and antagonists
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US20060121103A1 (en) * 2000-05-11 2006-06-08 Kenneth Kirby Transdermal delivery system
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
CN1525851A (en) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ Abuse-resistant controlled-release opioid dosage form
CN1273075C (en) * 2001-07-13 2006-09-06 爱科来株式会社 Analyzing apparatus, piercing element integrally installed body for temperature measuring device with analyzing apparatus, and body fluid sampling apparatus
SI1416842T1 (en) * 2001-07-18 2009-06-30 Euro Celtique Sa Pharmaceutical combinations of oxycodone and naloxone
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
ES2326794T3 (en) 2001-08-06 2009-10-20 Euro-Celtique S.A. FORMULATIONS OF OPIOID AGONISTS WITH LIBERABLE AND SEQUESTED ANTAGONISTS.
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
HUP0401022A3 (en) * 2001-08-14 2006-11-28 Biotie Therapies Corp Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
ES2546010T3 (en) 2002-04-05 2015-09-17 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
PT1551372T (en) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and metohds
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
EP1613324A2 (en) * 2003-04-14 2006-01-11 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US7910599B2 (en) 2005-01-10 2011-03-22 John David Sinclair Method for treating eating disorders by selective extinction with transdermal naloxone
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
PL2526932T3 (en) * 2006-06-19 2017-12-29 Alpharma Pharmaceuticals Llc Pharmaceutical composition
MX337286B (en) 2007-05-25 2016-02-22 Indivior Uk Ltd Sustained delivery formulations of risperidone compounds.
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2259780A2 (en) 2008-02-28 2010-12-15 Syntropharma Limited Pharmaceutical composition comprising naltrexone
ES2635733T3 (en) * 2008-07-07 2017-10-04 Euro-Celtique S.A. Use of opioid antagonists to treat urinary retention
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US11607026B2 (en) * 2014-05-30 2023-03-21 Johnson & Johnson Consumer Inc. Device for delivery of skin care composition
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
CN111447927A (en) * 2017-12-08 2020-07-24 帝国制药美国公司 Naloxone transdermal drug delivery device and method of use thereof
JP2023513781A (en) * 2020-02-14 2023-04-03 テイコク ファーマ ユーエスエー インコーポレーテッド Topical naloxone compositions and methods for using same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2837881A (en) * 1952-12-13 1958-06-10 Lawrence A Schneider Encapsulated product and method and apparatus for making same
US3249109A (en) * 1963-11-01 1966-05-03 Maeth Harry Topical dressing
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
IE49783B1 (en) * 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
US4629539A (en) * 1982-07-08 1986-12-16 Tdk Corporation Metal layer patterning method
WO1984000889A1 (en) * 1982-08-25 1984-03-15 Joel E Bernstein Method of treating pruritis and composition therefor
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4818540A (en) * 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
DE3545926A1 (en) * 1985-12-23 1987-07-02 Allan Gerhard Fruehauf Cloth or the like with capsules integrated therein and containing an active substance
EP0267617B1 (en) * 1986-11-14 1992-06-24 Theratech, Inc. Penetration enhancement with binary system of cell envelope disordering compounds and lower alcohols
DE3862405D1 (en) * 1987-03-09 1991-05-23 Alza Corp COMPOSITION FOR PREVENTING CONTACT ALLERGY BY SIMULTANEOUSLY ADMINISTERING A CORTICOSTEROID WITH A SENSITIZING MEDICINAL PRODUCT.
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response

Also Published As

Publication number Publication date
DK0429039T3 (en) 1995-03-27
ES2074513T3 (en) 1995-09-16
US5096715A (en) 1992-03-17
DE69017596D1 (en) 1995-04-13
NZ247173A (en) 1997-07-27
CA2030237C (en) 1997-12-30
AU6665090A (en) 1991-05-23
DE69017596T2 (en) 1995-07-06
AU639042B2 (en) 1993-07-15
EP0429039A3 (en) 1991-10-16
ATE119393T1 (en) 1995-03-15
NZ236104A (en) 1993-04-28
EP0429039B1 (en) 1995-03-08
EP0429039A2 (en) 1991-05-29
FI905718A (en) 1991-05-21
FI905718A0 (en) 1990-11-20

Similar Documents

Publication Publication Date Title
AU6665090A (en) Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
JPS55162716A (en) Medicinal composition
AU3634889A (en) Method for treating alcoholism by extinguishing the alcohol-drinking response
AU6476496A (en) Novel formulations for transdermal delivery of pergolide
AU7921887A (en) Therapeutic agents
DE69214230T2 (en) Codeinone derivatives and their pharmaceutical use
AU7085996A (en) Therapeutic preparation for the transdermal application of active substances through the skin
EP0489108A4 (en) Method and composition for the treatment of cutaneous, ocular, and mucosal hypersensitivity, inflammation, and hyperproliferative conditions using topical preparations of serotonin antagonists
WO1995013071A3 (en) Treatment of immunoregulatory disorders
GB1390772A (en) Oral narcotic composition
GEP19991686B (en) Pharmaceutical Composition for Obtaining Effervescent Powder or Tablet, Pharmaceutical Preparation and Method for Preparing Same
HUT70150A (en) Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridines, pharmaceutical compositions containing them and method for its preparation
DE59400446D1 (en) Shower system with an alkali and / or metal sensitive, pharmaceutical active ingredient, and process for its manufacture
RU95105973A (en) Method of toxoplasmosis severity decrease, pharmaceutical composition, use of rifamycin derivatives for preparing the medicinal preparations for toxoplasmosis treatment
DE3866408D1 (en) SELF-ADHESIVE DEVICE FOR TRANSDERMAL ADMINISTRATION OF AN ACTIVE SUBSTANCE.
CA2069608A1 (en) Substituted 4-phenyl-4-piperidinecarboxamides with both local anaesthetic and analgesic effect as well as processes for their preparation
HU902098D0 (en) Process for producing substituted 1,8-naphthyridine derivatives and pharmaceutical preparatives containing such compounds
IL104005A0 (en) Piperidylmethyl-substituted chroman derivatives,their preparation and pharmaceutical compositions containing them
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
AU2908389A (en) Device for administering medicaments by atomization in intubated or tracheotomized patients
DE3881254D1 (en) PHARMACEUTICAL COMPOSITION.
SU1744810A1 (en) Vasoactive agent "dimephosphone" normalizing vegetative nervous system functions
DE3873770D1 (en) A PHARMACEUTICAL COMPOSITION ADAPTED TO THE TRANSDERMAL APPLICATION OF AN OPIOID.
CA2235617A1 (en) Therapeutic preparation for the transdermal administration of active substances
ZA876116B (en) Pharmaceutical preparation for administration by percutaneous absorption and method for its manufacture

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry